Market Overview

UPDATE: Morgan Stanley Upgrades Forest Laboratories Ahead of Further Financial Upside

Related FRX
Activis Shares Languish Post-Forest Deal
Among A Raft Of Index Changes, Affiliated Managers Group To Join S&P 500
Forest Labs to Buy Furiex Pharma in $1.5B Deal (Fox Business)

In a report published Tuesday, Morgan Stanley analyst David Risinger upgraded the rating on Forest Laboratories (NYSE: FRX) from Equal-Weight to Overweight, and named an $86.00 price target.

In the report, Morgan Stanley noted, “Our Base Case is an earnings and multiple call: cons under-estimates durability of growth. We raised F15E (Mar) EPS 25% from $3.13 to $3.90 (5% above cons) and F16E EPS 23% from $3.86 to $4.73 (9% above cons). Cons is not fully updated for the Aptalis close Feb 3rd, but we believe investors under-appreciate Namenda earnings durability in the wake of the hard conversion to longer patent life XR announced late-Friday Feb 14th. We est. Forest F16-F21 5-yr EPS CAGR of 8%, and we believe cons under-estimates durability of growth and P/E will rise.”

Forest Laboratories closed on Friday at $71.39.

Latest Ratings for FRX

DateFirmActionFromTo
May 2014UBSMaintainsNeutral
Apr 2014Cantor FitzgeraldMaintainsHold
Apr 2014SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for FRX
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Upgrades Analyst Ratings

 

Related Articles (FRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional